Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 15;7(11):12477-88.
doi: 10.18632/oncotarget.7245.

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Hojjat Ahmadzadehfar  1 , Elisabeth Eppard  1 , Stefan Kürpig  1 , Rolf Fimmers  2 , Anna Yordanova  1 , Carl Diedrich Schlenkhoff  1 , Florian Gärtner  1 , Sebastian Rogenhofer  3 , Markus Essler  1
Affiliations

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Hojjat Ahmadzadehfar et al. Oncotarget. .

Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75.2 years (range: 64-82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17-2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79.1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68.2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

Keywords: 177Lu; PSA; PSMA; prostate cancer; radioligand therapy.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no financial and non-financial competing interests.

Figures

Figure 1
Figure 1. Waterfall plot showing percentage PSA change from baseline at 8 weeks after the first cycle in 23 patients (one patient with multiple liver metastasis died 10 weeks after the first cycle)
79.1 % of patients showed any PSA decline. 41.6 % of patients showed more than 50 % PSA decline.
Figure 2
Figure 2. Waterfall plot showing percentage PSA change from baseline at 8 weeks after the second cycle in 19 patients /22
(3 patients died within 10 weeks after the second cycle).
Figure 3
Figure 3. A 75-year-old patient with diffuse bone and lymph node metastases as well as local recurrence
(left MIP image). History of chemotherapy and therapy with abiretarone, PSA elevation under enzalutamide. The patient underwent PSMA therapy as the last possible option. Continuing PSA decline and partial response in Ga-PSMA PET images after the first (middle MIP image) and second cycles (right MIP image).
Figure 4
Figure 4. Hematotoxicity 2 months after the last cycle according to CTC criteria
Figure 5
Figure 5. Nephrotoxocity 2 months after the last cycle according to CTC criteria
Figure 6
Figure 6. Hepatotoxocity 2 months after the last cycle according to CTC criteria
Figure 7
Figure 7
Ga-PSMA PET images A&B. of a 72-year-old patient with diffuse bone and lymph node metastases (yellow arrows show the enlarged lymph nodes) received two cycles of Lu-PSMA. Ga-PSMA PET images C&D. 2 months after the second cycle show a very good response with reduction in PSMA expression as well as a size reduction of the lymph node metastases in CT B&D.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136:E359–386. - PubMed
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010;60:277–300. - PubMed
    1. Wei Q, Li M, Fu X, Tang R, Na Y, Jiang M, Li Y. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate cancer and prostatic diseases. 2007;10:167–174. - PubMed
    1. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. Journal of biological regulators and homeostatic agents. 2014;28:555–563. - PubMed
    1. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, Kopka K, Haberkorn U. [Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2015;42:987–988. - PubMed

MeSH terms